Literature DB >> 30996785

Investigation on 2',3'-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists.

Diego Dal Ben1, Michela Buccioni1, Catia Lambertucci1, Gabriella Marucci1, Andrea Spinaci1, Anna Marchenkova2, Aliaa Abdelrahman3, Andrea Nistri2, Christa E Müller3, Rosaria Volpini1.   

Abstract

Antagonists of the purinergic P2X3 receptors represent promising drugs for the treatment of inflammation and pain. The ATP derivative 2',3'-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP) has been described as a potent competitive inhibitor of this receptor. In this work, the design and synthesis of novel TNP-ATP analogues bearing alkyl groups in the 2',3'-position are reported. These compounds were biologically evaluated as P2X3 antagonists using the patch clamp recording technique on mouse trigeminal ganglionic sensory neurons. Some of the compounds showed nanomolar inhibitory potency for the P2X3 receptor. Further modification of these derivatives was made by substitution of the triphosphate chain with different acidic groups. All compounds were additionally tested at five human P2X receptor subtypes stably expressed in 1321N1 astrocytoma cells to evaluate their potency and P2X3 selectivity. Results confirmed the P2X3 antagonist potency for some derivatives.

Entities:  

Year:  2018        PMID: 30996785      PMCID: PMC6466514          DOI: 10.1021/acsmedchemlett.8b00524

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

1.  Competitive antagonism of recombinant P2X(2/3) receptors by 2', 3'-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP).

Authors:  E C Burgard; W Niforatos; T van Biesen; K J Lynch; K L Kage; E Touma; E A Kowaluk; M F Jarvis
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  Emerging structures and ligands for P2X(3) and P2X(4) receptors-towards novel treatments of neuropathic pain.

Authors:  Christa E Müller
Journal:  Purinergic Signal       Date:  2010-05-16       Impact factor: 3.765

3.  Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.

Authors:  Christine E Brotherton-Pleiss; Michael P Dillon; Anthony P D W Ford; Joel R Gever; David S Carter; Shelley K Gleason; Clara J Lin; Amy G Moore; Anthony W Thompson; Marzia Villa; Yansheng Zhai
Journal:  Bioorg Med Chem Lett       Date:  2009-12-16       Impact factor: 2.823

4.  A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat.

Authors:  Michael F Jarvis; Edward C Burgard; Steve McGaraughty; Prisca Honore; Kevin Lynch; Timothy J Brennan; Alberto Subieta; Tim Van Biesen; Jayne Cartmell; Bruce Bianchi; Wende Niforatos; Karen Kage; Haixia Yu; Joe Mikusa; Carol T Wismer; Chang Z Zhu; Katharine Chu; Chih-Hung Lee; Andrew O Stewart; James Polakowski; Bryan F Cox; Elizabeth Kowaluk; Michael Williams; James Sullivan; Connie Faltynek
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

Review 5.  P2X receptors in health and disease.

Authors:  G Burnstock; C Kennedy
Journal:  Adv Pharmacol       Date:  2011

6.  AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.

Authors:  Joel R Gever; Rothschild Soto; Robert A Henningsen; Renee S Martin; David H Hackos; Sandip Panicker; Werner Rubas; Ian B Oglesby; Michael P Dillon; Marcos E Milla; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

7.  Adenine-based acyclic nucleotides as novel P2X3 receptor ligands.

Authors:  Rosaria Volpini; Ram Chandra Mishra; Dhuldeo D Kachare; Diego Dal Ben; Catia Lambertucci; Ippolito Antonini; Sauro Vittori; Gabriella Marucci; Elena Sokolova; Andrea Nistri; Gloria Cristalli
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 8.  Molecular physiology of P2X receptors.

Authors:  R Alan North
Journal:  Physiol Rev       Date:  2002-10       Impact factor: 37.312

9.  Agonist-dependence of recovery from desensitization of P2X(3) receptors provides a novel and sensitive approach for their rapid up or downregulation.

Authors:  Elena Sokolova; Andrei Skorinkin; Elsa Fabbretti; Lara Masten; Andrea Nistri; Rashid Giniatullin
Journal:  Br J Pharmacol       Date:  2004-02-23       Impact factor: 8.739

10.  Comparison of P2X and TRPV1 receptors in ganglia or primary culture of trigeminal neurons and their modulation by NGF or serotonin.

Authors:  Manuela Simonetti; Alessandra Fabbro; Marianna D'Arco; Marina Zweyer; Andrea Nistri; Rashid Giniatullin; Elsa Fabbretti
Journal:  Mol Pain       Date:  2006-03-28       Impact factor: 3.395

View more
  1 in total

Review 1.  Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.

Authors:  Peter Illes; Christa E Müller; Kenneth A Jacobson; Thomas Grutter; Annette Nicke; Samuel J Fountain; Charles Kennedy; Günther Schmalzing; Michael F Jarvis; Stanko S Stojilkovic; Brian F King; Francesco Di Virgilio
Journal:  Br J Pharmacol       Date:  2020-12-21       Impact factor: 9.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.